Search

Petr F Kuzma

age ~80

from Princeton, NJ

Get Report
Also known as:
  • Peter G Kuzma
  • Peter F Kuzma
  • Pete G Kuzma
  • Peterf Kuzma
Phone and address:
4 Brook Dr E, Princeton, NJ 08540
609-430-1709
Related to:
Connected to:

Petr Kuzma Phones & Addresses

  • 4 Brook Dr E, Princeton, NJ 08540 • 609-430-1709
  • Barnegat Light, NJ
  • Barnegat, NJ
  • Valley Village, CA
  • Toms River, NJ
  • Dayton, NJ
  • Audubon, NJ
  • Los Angeles, CA
  • Monmouth Junction, NJ

Work

  • Company:
    Kingston pharmaceutical consulting
    Jan 2011
  • Position:
    President

Education

  • Degree:
    Bachelors, Bachelor of Science
  • School / High School:
    Saint Peter's University
    1972 to 1976
  • Specialities:
    Organic Chemistry

Skills

Medical Devices • R&D • Drug Delivery • Fda • Pharmaceutical Industry • Drug Development • Biotechnology • Technology Transfer • Clinical Development • Polymers • Biopharmaceuticals • Regulatory Affairs • Clinical Trials • Validation • Sop • Glp • Drug Discovery • V&V • Regulatory Submissions • Pharmaceutics • Gmp • Cross Functional Team Leadership • Oncology • Product Launch • Commercialization • Chemistry • Infectious Diseases • Patents • Formulation • Lifesciences • Analytical Chemistry • Medical Polymer Expertise • Design Control • Gxp • Cardiology • Gcp • Quality System • Chromatography • Development of Implantable Drug Delivery... • Cro • 21 Cfr Part 11 • Capa • Protein Chemistry • Change Control • Iso 13485 • Process Simulation • Fda Regulatory Support • Pre Clinical and Clinical Testing • More Than 20 Patents Issued

Languages

English • Czech

Industries

Pharmaceuticals
Name / Title
Company / Classification
Phones & Addresses
Petr F Kuzma
Vice President
VALERA PHARMACEUTICALS, INC
8 Clarke Dr, Cranbury, NJ 08512

Resumes

Petr Kuzma Photo 1

President

view source
Location:
Princeton, NJ
Industry:
Pharmaceuticals
Work:
Kingston Pharmaceutical Consulting
President
Endo Pharmaceuticals Jan 2009 - Dec 2010
Vp, R and D
Valera Pharmaceuticals Jan 2003 - Jan 2009
Vp, R and D
Indevus Pharmaceuticals Apr 2007 - Jan 2009
Svp, R and D
Hydro Med Sciences Jan 1999 - Jan 2003
Vp, R and D and Business Development
Education:
Saint Peter's University 1972 - 1976
Bachelors, Bachelor of Science, Organic Chemistry Institute of Industrial Chemistry
Associates Rutgers University
Skills:
Medical Devices
R&D
Drug Delivery
Fda
Pharmaceutical Industry
Drug Development
Biotechnology
Technology Transfer
Clinical Development
Polymers
Biopharmaceuticals
Regulatory Affairs
Clinical Trials
Validation
Sop
Glp
Drug Discovery
V&V
Regulatory Submissions
Pharmaceutics
Gmp
Cross Functional Team Leadership
Oncology
Product Launch
Commercialization
Chemistry
Infectious Diseases
Patents
Formulation
Lifesciences
Analytical Chemistry
Medical Polymer Expertise
Design Control
Gxp
Cardiology
Gcp
Quality System
Chromatography
Development of Implantable Drug Delivery Medical Devices
Cro
21 Cfr Part 11
Capa
Protein Chemistry
Change Control
Iso 13485
Process Simulation
Fda Regulatory Support
Pre Clinical and Clinical Testing
More Than 20 Patents Issued
Languages:
English
Czech

Us Patents

  • Hydrogel Compositions Useful For The Sustained Release Of Macromolecules And Methods Of Making Same

    view source
  • US Patent:
    6361797, Mar 26, 2002
  • Filed:
    Dec 7, 2000
  • Appl. No.:
    09/646066
  • Inventors:
    Petr Kuzma - Princeton NJ
    Harry Quandt - Bensalem PA
  • Assignee:
    Hydro Med Sciences, Inc. - Wilmington DE
  • International Classification:
    A61K 914
  • US Classification:
    424486, 424422, 424423, 424473
  • Abstract:
    A method of producing a homogenous porous hydrogel useful for drug delivery is described. The pores of the hydrogel are created by diffusion enhancers to facilitate sustained delivery of macromolecules. Also described are various articles produced from these hydrogels.

  • Controlled Release Formulations Of Octreotide

    view source
  • US Patent:
    7452868, Nov 18, 2008
  • Filed:
    Mar 10, 2006
  • Appl. No.:
    11/372749
  • Inventors:
    Petr Kuzma - Princeton NJ, US
    Stephanie Decker - Princeton NJ, US
  • Assignee:
    Indevus Pharmaceuticals, Inc. - Lexington MA
  • International Classification:
    A61K 38/08
    A61K 9/52
  • US Classification:
    514 16, 424422, 424461, 424462, 5263297
  • Abstract:
    A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.

  • Delivery Of Dry Formulations Of Octreotide

    view source
  • US Patent:
    7759312, Jul 20, 2010
  • Filed:
    Jul 11, 2008
  • Appl. No.:
    12/171999
  • Inventors:
    Petr Kuzma - Princeton NJ, US
    Stefanie Decker - Princeton NJ, US
  • Assignee:
    Endo Pharmaceuticals Solutions Inc. - Chadds Ford PA
  • International Classification:
    A61K 38/08
    A61K 9/52
  • US Classification:
    514 16, 424422, 424461, 424462
  • Abstract:
    Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.

  • Controlled Release Formulations Of Octreotide

    view source
  • US Patent:
    7803773, Sep 28, 2010
  • Filed:
    Sep 29, 2008
  • Appl. No.:
    12/240690
  • Inventors:
    Petr Kuzma - Princeton NJ, US
    Stefanie Decker - Princeton NJ, US
  • Assignee:
    Endo Pharmaceuticals Solutions Inc. - Chadds Ford PA
  • International Classification:
    A61K 38/08
    A61K 9/52
  • US Classification:
    514 16, 424422, 424461, 424462
  • Abstract:
    A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.

  • Long Term Drug Delivery Devices With Polyurethane Based Polymers And Their Manufacture

    view source
  • US Patent:
    7842303, Nov 30, 2010
  • Filed:
    Aug 10, 2004
  • Appl. No.:
    10/915625
  • Inventors:
    Sheng-hung Kuo - Plainsboro NJ, US
    Petr Kuzma - Princeton NJ, US
  • Assignee:
    Indevus Pharmaceuticals, Inc. - Lexington MA
  • International Classification:
    A61F 2/00
  • US Classification:
    424423, 606194, 6048901
  • Abstract:
    This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises:.

  • Long Term Drug Delivery Devices With Polyurethane Based Polymers And Their Manufacture

    view source
  • US Patent:
    7858110, Dec 28, 2010
  • Filed:
    Sep 30, 2008
  • Appl. No.:
    12/242497
  • Inventors:
    Petr Kuzma - Princeton NJ, US
    Harry Quandt - Bensalem PA, US
  • Assignee:
    Endo Pharmaceuticals Solutions, Inc. - Chadds Ford PA
  • International Classification:
    A61F 2/00
  • US Classification:
    424423, 606194, 6048901
  • Abstract:
    This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.

  • Octreotide Implant Having A Release Agent And Uses Thereof

    view source
  • US Patent:
    7960335, Jun 14, 2011
  • Filed:
    Jun 24, 2009
  • Appl. No.:
    12/490979
  • Inventors:
    Petr Kuzma - Princeton NJ, US
    Stefanie Decker - Princeton NJ, US
    Harry Quandt - Bensalem PA, US
  • Assignee:
    Endo Pharmaceuticals Solutions Inc. - Chadds Ford PA
  • International Classification:
    A61K 38/00
    A61K 9/52
  • US Classification:
    514 11, 514 217, 424422, 424460
  • Abstract:
    Methods, formulations and kits are described that allow for the controlled release of octreotide, e. g. , octreotide acetate, in a subject.

  • Compositions And Methods For Treating Precocious Puberty

    view source
  • US Patent:
    8062652, Nov 22, 2011
  • Filed:
    Jun 17, 2005
  • Appl. No.:
    11/155822
  • Inventors:
    Petr Kuzma - Princeton NJ, US
  • Assignee:
    Endo Pharmaceuticals Solutions Inc. - Chadds Ford PA
  • International Classification:
    A61F 2/00
    A61K 38/00
    A61K 38/09
    A61K 31/765
    A61P 5/02
    A01N 31/14
  • US Classification:
    424423, 514 11, 514 103, 5147224, 514899
  • Abstract:
    The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
Get Report for Petr F Kuzma from Princeton, NJ, age ~80
Control profile